Revium Rx. 8-K

What Happened Revium Rx. filed an 8-K (Item 5.02) on June 1, 2026, disclosing that Arie Gordashnikov resigned as Chief Financial Officer of Revium and its subsidiaries effective May 27, 2026. The company’s Board simultaneously appointed Igor Bluvstein as the new Chief Financial Officer, also effective May 27, 2026. The filing states Mr. Gordashnikov’s resignation was not due to any disagreement with the company.

Key Details

• Resignation effective date: May 27, 2026 — Arie Gordashnikov stepped down as CFO.
• Appointment effective date: May 27, 2026 — Igor Bluvstein named CFO of Revium and its subsidiaries.
• Background on incoming CFO: Mr. Bluvstein, age 44, has over 17 years of financial leadership experience, including CFO roles at Argent BioPharma Ltd. (2024–2025) and G Medical Innovations Holdings Ltd. (2022–2024). He holds a BA in Accounting & Economics (Open University of Israel) and is a CPA.
• Compensation disclosed: Mr. Bluvstein will receive a monthly retainer of NIS 17,000 plus VAT.

Why It Matters A CFO transition is a material change in corporate leadership that can affect financial reporting, investor communications, and internal controls. Revium has disclosed immediate continuity by appointing an experienced finance executive; investors should note the effective date and the modest disclosed retainer. Watch for any future SEC filings (e.g., employment agreements, background disclosures, or changes to financial guidance) for additional details that could affect the company’s financial oversight or costs.